Innovations in Blood Cancer Treatment: Navigating CAR T-cell and Bispecific Therapies

New In-Person Event: Pre-Registration Required
*Registrants can visit the LLS' Booth #1032 on Thursday, 4/10/25, to receive a fast pass for quicker entrance into the symposium*

Dinner Symposium will be held during the Oncology Nursing Society’s (ONS) 50^th Annual Congress*
*Participants must be registered for the ONS Annual Congress in order to attend this session: https://www.ons.org/congress/2025/homepage

Presentation and dinner: 6:00 – 7:30 PM MT
*Doors open at 5:30 PM for check-in and dinner with education starting at 6:00 PM.

Meeting space has been assigned to provide a symposium supported by The Leukemia & Lymphoma Society during the Oncology Nursing Society’s (ONS) 50^th Annual Congress, April 9 – April 13, 2025 in Denver, CO. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.

Target Audience

This CE activity is intended for oncology nurses and nurse practitioners involved in the care of patients with hematologic malignancies.

Description

Compete with your colleagues to win prizes and earn free CE credit, as you deepen your expertise on the availability and application of CAR T-cell and bispecific therapies to treat patients with hematologic malignancies. Learn about treatment protocols and procedures, identifying and managing common adverse events, and management of bispecific therapy in the community. 
Broaden your understanding of the newest treatments, safety and efficacy, patient management, disparities in care, resources for patient education and support from The Leukemia & Lymphoma Society, and more in this interactive session, to improve patient care!

Educational Objectives

Upon completion, participants should be better able to:

• Describe the principles and mechanisms of CAR T- cell and bispecific therapies in treating blood cancers
• Identify clinical indications, including recent FDA approvals and therapies in clinical trials, and disparities in care 
• Explain treatment protocols, including pre-treatment conditioning, infusion procedures, identifying and managing common adverse events, management of bispecific therapy in the community, and strategies to improve patient-centered care
• Assess the efficacy of CAR T-cell and bispecific therapies to make informed decisions about treatment options
• List resources and education to support patients, caregivers, and healthcare professionals

Faculty

Tara M Graff, DO, MS
Medical Oncologist
Director of Clinical Trials 
Mission Cancer and Blood/UIHSMG
Director of Cellular Therapy 
ONCare Alliance
Des Moines, IA

Jonathan Gutman, MD
Director of Cellular Therapies 
Professor, Medicine-Hematology
University of Colorado 
Aurora, CO

Michelle McDaniel, RN, CIONS President
Mission Cancer
Des Moines, IA

Samantha Schad, MSN, RN, OCN, WTA-C
Oncology Clinical Practice Leader
Hospital of the University of Pennsylvania
Philadelphia, PA

Continuing Education Information

Nursing Continuing Professional Development Contact Hours
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing. 

ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (OCN, CBCN, CPHON AOCNP) 1.0*, Foundations of Transplant (BMTCN) 1.0*, Oncologic Emergencies (OCN, CPHON, AOCNP) 1.0*, Oncology Nursing Practice (OCN) 1.0*, Professional Practice /Performance (BMTCN, AOCNP) 0.5*, Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN) 0.5*, Quality of Life (BMTCN) 0.5*, Roles of the APRN (AOCNP) 0.5*, Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) 1.0*, Transplant Process and Infusion (BMTCN) 1.0*, Treatment (OCN, CBCN, AOCNP, CPHON) 1.5*.
Total points: 1.5
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum amount of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Provider
This activity is provided by The Leukemia & Lymphoma Society.  

Support
This activity is supported by Autolus Therapeutics.
 

REGISTER NOW

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.